» Articles » PMID: 8214276

Predictors of Treatment Failure in Multiple Drug-resistant Falciparum Malaria: Results from a 42-day Follow-up of 224 Patients in Eastern Thailand

Overview
Specialty Tropical Medicine
Date 1993 Oct 1
PMID 8214276
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

We report here the results of a 42-day follow-up of 224 patients treated with mefloquine for uncomplicated falciparum malaria in Eastern Thailand. The risk of treatment failure among the 209 patients who completed the follow-up was 57% (95% confidence interval [CI] = 50,64). The daily risk of treatment failure, estimated through an exponential survival function, was constant during the follow-up period and equal to 1.9%. Five patient characteristics were found to be independent and important predictors of treatment failure in a Cox proportional hazards model: a young age (adjusted hazard ratio [AHR] for an increase of 10 years of age = 0.75 [95% CI = 0.62, 0.90]); a history of at least three documented mefloquine treatments in the past year (AHR = 1.89 [95% CI = 1.10, 3.24]); a parasitemia count > 100,000/microliter (AHR = 1.80 [95% CI = 1.16, 2.80]); and a history of diarrhea in the first two days after treatment (AHR = 1.51 [95% CI = 0.99, 2.31]). A hemoglobin level < or = 10 g/dl on the day of consultation was also a predictor of treatment failure, but only among patients who had been treated for malaria in the past 120 days (AHR = 4.38 [95% CI = 1.55, 12.1]). These latter patients may have become anemic while they were unsuccessfully treated with mefloquine for an infection by a multiple drug-resistant strain in the past 120 days.(ABSTRACT TRUNCATED AT 250 WORDS)

Citing Articles

Artemisinin-based combination therapy in pregnant women in Zambia: efficacy, safety and risk of recurrent malaria.

Nambozi M, Kabuya J, Hachizovu S, Mwakazanga D, Mulenga J, Kasongo W Malar J. 2017; 16(1):199.

PMID: 28511713 PMC: 5434531. DOI: 10.1186/s12936-017-1851-7.


Gametocyte dynamics and the role of drugs in reducing the transmission potential of Plasmodium vivax.

Douglas N, Simpson J, Phyo A, Siswantoro H, Hasugian A, Kenangalem E J Infect Dis. 2013; 208(5):801-12.

PMID: 23766527 PMC: 3733516. DOI: 10.1093/infdis/jit261.


Plasmodium vivax recurrence following falciparum and mixed species malaria: risk factors and effect of antimalarial kinetics.

Douglas N, Nosten F, Ashley E, Phaiphun L, van Vugt M, Singhasivanon P Clin Infect Dis. 2011; 52(5):612-20.

PMID: 21292666 PMC: 3060895. DOI: 10.1093/cid/ciq249.


Factors contributing to delay in parasite clearance in uncomplicated falciparum malaria in children.

Sowunmi A, Adewoye E, Gbotsho G, Happi C, Sijuade A, Folarin O Malar J. 2010; 9:53.

PMID: 20156350 PMC: 2834701. DOI: 10.1186/1475-2875-9-53.


Efficacy of sulphadoxine-pyrimethamine with or without artesunate for the treatment of uncomplicated Plasmodium falciparum malaria in southern Mozambique: a randomized controlled trial.

Allen E, Little F, Camba T, Cassam Y, Raman J, Boulle A Malar J. 2009; 8:141.

PMID: 19558654 PMC: 2709115. DOI: 10.1186/1475-2875-8-141.